Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference
Synlogic, a clinical-stage biotechnology company (Nasdaq: SYBX), will participate in the National PKU Alliance's biennial conference from July 7-10, 2022, in Vancouver, Washington. As an event sponsor, Synlogic will present on emerging therapies for phenylketonuria (PKU) and share research data on dietary protein intake in PKU patients. Key presentations include:
- Transforming Medicine through Synthetic Biology - July 8, 2022, at 3:30 P.M. PT
- Characterization of Dietary Protein Intake in PKU Patients - July 9, 2022, at 3:00 P.M. PT
Synlogic focuses on developing synthetic biology medicines for metabolic diseases.
- None.
- None.
VANCOUVER, Wash., June 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, announced today it will participate at the National PKU Alliance’s (NPKUA) biennial conference July 7-10, 2022 in Vancouver, Washington. As an event sponsor, Synlogic has been invited to present during the session “What’s New in PKU? (Emerging Therapies, Research, Foods & Beyond).” In addition, the team will share data on dietary protein intake in PKU patients during a poster presentation.
Presentation:
- Title: Transforming Medicine through Synthetic Biology
- Presenter: Dr. Marja Puurunen, MD, Ph.D, Therapeutic Area Lead, Executive Medical Director
- Date and Time: Friday, July 8, 2022; 3:30 P.M. PT
Poster:
- Title: Characterization of Dietary Protein Intake in PKU Patients
- Presenter: Dr. Marja Puurunen, MD, Ph.D, Therapeutic Area Lead, Executive Medical Director
- Date and Time: Saturday, July 9, 2022; 3:00 P.M. PT
About Synlogic
Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic’s reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. In addition to its clinical programs, Synlogic has research collaborations with Roche on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks on additional undisclosed preclinical assets. For additional information visit www.synlogictx.com.
Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," “look forward,” "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic, may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of SYNB1618, SYNB1934, SYNB1353 and SYNB8802 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.
SOURCE Synlogic, Inc.
Media Contact:
Bill Berry
Berry & Company Public Relations
212-253-8881; bberry@berrypr.com
Investor Contact:
Andrew Funderburk
Kendall Investor Relations
617-914-0008; afunderburk@kendallir.com
FAQ
What is Synlogic's participation in the National PKU Alliance conference?
What presentations will Synlogic give at the NPKUA conference?
What is the significance of Synlogic's PKU program?
What are the future plans for Synlogic's drug candidates?
